Extirpative surgery for all patients with upper tract urothelial carcinoma (UTUC) risks overtreatment and associated morbidity. Endoscopic approaches are particularly applicable for low-risk disease albeit with the potential for ipsilateral upper tract recurrence. Adjuvant and ablative intracavitary therapies are current and future strategies that could improve disease outcomes and increase adoption of kidney preservation for UTUC.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Raman, J. D., Messer, J., Sielatycki, J. A. & Hollenbeak, C. S. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. 107, 1059–1064 (2011).
Seisen, T. et al. Oncologic outcomes of kidney sparing surgery versus radical nephroureterectomy for the elective treatment of clinically organ confined upper tract urothelial carcinoma of the distal ureter. J. Urol. 195, 1354–1361 (2016).
Roupret, M. et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur. Urol. 73, 111–122 (2018).
Upfill-Brown, A. et al. Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines. World J. Urol. 37, 1157–1164 (2019).
Margulis, V. et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115, 1224–1233 (2009).
Petros, F. G. Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. Urol. Oncol. 37, 292.e1–292.e9 (2019).
Petros, F. G., Li, R. & Matin, S. F. Endoscopic approaches to upper tract urothelial carcinoma. Urol. Clin. North Am. 45, 267–286 (2018).
Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J. Urol. 196, 1021–1029 (2016).
Gallioli, A. et al. Adjuvant single-dose upper urinary tract instillation of mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: a single-centre prospective non-randomized trial. J. Endourol. https://doi.org/10.1089/end.2019.0750 (2020).
Kleinmann, N. et al. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30147-9 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.D.R. declares that he is a study site investigator for the OLYMPUS trial (NCT02793128) and a member of the strategic advisory board for Urogen Pharma Ltd.
Rights and permissions
About this article
Cite this article
Raman, J.D. Adjuvant and ablative therapies for low-risk UTUC: avenues to enhance kidney preservation. Nat Rev Urol 17, 433–434 (2020). https://doi.org/10.1038/s41585-020-0338-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-020-0338-4
